Skip to contents

Daniel Hal Solomon, MD, MPH
Associate Physician, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Rheumatology, Immunology
75 Francis Street
Boston, MA 02115

Research Email:

Edit Profile

Research Narrative:
            Dr. Solomon is a population scientist focusing on the epidemiology and health services of rheumatic disease. He serves as the Chief of the Section of Clinical Sciences in the Division of Rheumatology at BWH. His research work is primarily funded by the NIH, AHRQ, and foundations. He has served major roles at the American College of Rheumatology and within the osteoporosis community as well. 
His achievements in population science research focuses on three areas. First, he has been a leading investigator on the cardiovascular safety of nonsteroidal anti-inflammatory drugs (NSAIDs). He has been the first author on 12 original articles in this area, has several industry-sponsored grants and one AHRQ sponsored grant in this area, and led the American College of Rheumatology Blue Ribbon Panel to set recommendations for NSAIDs. He has given over 15 invited talks on this topic and currently serve on the Executive Committee of the largest randomized controlled trial on the cardiovascular safety of NSAIDs and selective COX-2 inhibitors.
 Second, he has focused much of his research on cardiovascular manifestations of rheumatoid arthritis and its treatment. He completed one NIH grant on this topic and have another current NIH grant to study insulin and glucose metabolism in rheumatoid arthritis. He is the first author on 5 publications describing the epidemiology of cardiovascular disease in patients with rheumatoid arthritis and has given 8 invited lectures in this area.
Finally, he has helped define standards for osteoporosis care improvement. He has received two NIH grants in this area. A current NIH funded study is a large-scale adherence improvement trial for osteoporosis medications. He has first authored 8 original articles in this area and given 10 invited lectures on osteoporosis improvement. He serves on the steering committee of the National Action Plan for Bone Health, focusing on methods to improve dissemination of proven improvement methods, as well as on the American Orthopaedic Association’s Own the Bone Program.
               He teaches and mentors primarily in rheumatic disease epidemiology and pharmacoepidemiology.   He has mentored over 25 fellows and trainees and have a K24 award from NIH with 25% effort devoted to research training and mentoring. He developed and directed a course in clinical research for rheumatologists. As well, he teaches residents in the BWH Department of Medicine’s lecture series and journal club.

Investigative Interests:  drug safety and effectiveness

Harvard School of Public Health, 1998, MPH
Yale School of Medicine, 1992, MD

American College of Rheumatology Young Investigator Award
NIH Mentoring Award
Chief, Section of Clinical Sciences, Rheumatology
Co-Director, Patient-Centered Research Center

Publications (Pulled from Harvard Catalyst Profiles):

1. Lalani R, Lyu H, Vanni K, Solomon DH. Low Dose Methotrexate and Mucocutaneous Adverse Events: Results of a Systematic Literature Review and Meta-Analysis of Randomized Controlled Trials. Arthritis Care Res (Hoboken). 2019 May 31.

2. Yoshida K, Solomon DH, Haneuse S, Kim SC, Patorno E, Tedeschi SK, Lyu H, Hernández-Díaz S, Glynn RJ. A tool for empirical equipoise assessment in multigroup comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2019 May 27.

3. Zhao SS, Ermann J, Xu C, Lyu H, Tedeschi SK, Liao KP, Yoshida K, Moots RJ, Goodson NJ, Solomon DH. Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. Rheumatology (Oxford). 2019 May 12.

4. Lyu H, Jundi B, Xu C, Tedeschi SK, Yoshida K, Zhao S, Nigwekar SU, Leder BZ, Solomon DH. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2019 May 01; 104(5):1753-1765.

5. Sung YK, Yoshida K, Prince FHM, Frits ML, Cho SK, Choe JY, Lee HS, Lee J, Lee SS, Yoo DH, Helfgott SM, Shadick NA, Weinblatt ME, Solomon DH, Bae SC. Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS One. 2019; 14(4):e0214981.

6. Liao KP, Solomon DH. Lipids and cardiovascular risk through the lens of rheumatoid arthritis. Arthritis Rheumatol. 2019 Apr 15.

7. Mitchell DM, Ruppert K, Udupa N, Bassir F, Darakananda K, Solomon DH, Lian Y, Cauley JA, Karlamangla AS, Greendale GA, Finkelstein JS, Burnett-Bowie SM. Temporal increases in 25-hydroxyvitamin D in midlife women: Longitudinal results from the Study of Women's Health Across the Nation. Clin Endocrinol (Oxf). 2019 Apr 10.

8. Desai RJ, Jin Y, Franklin PD, Lee YC, Bateman BT, Lii J, Solomon DH, Katz JN, Kim SC. Association of Geography and Access to Health Care Providers With Long-Term Prescription Opioid Use in Medicare Patients With Severe Osteoarthritis: A Cohort Study. Arthritis Rheumatol. 2019 May; 71(5):712-721.

9. Sparks JA, Lesperance T, Accortt NA, Solomon DH. Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment. Arthritis Care Res (Hoboken). 2019 Apr; 71(4):512-520.

10. Bucala RJ, Solomon DH. Trust in Publication: Now More than Ever. Arthritis Rheumatol. 2019 Mar 12.